153 related articles for article (PubMed ID: 11975834)
1. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
Cheng-Lai A
Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
[TBL] [Abstract][Full Text] [Related]
2. Eprosartan: a review of its use in the management of hypertension.
Plosker GL; Foster RH
Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
[TBL] [Abstract][Full Text] [Related]
3. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
4. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
5. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
6. Eprosartan.
McClellan KJ; Balfour JA
Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of eprosartan.
Weber M
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):95S-101S. PubMed ID: 10213528
[TBL] [Abstract][Full Text] [Related]
8. Eprosartan: a review of its use in hypertension.
Plosker GL
Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
[TBL] [Abstract][Full Text] [Related]
9. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
10. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
Hedner T; Himmelmann A
J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
[TBL] [Abstract][Full Text] [Related]
12. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg NK
Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
[TBL] [Abstract][Full Text] [Related]
13. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
15. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
Shusterman NH
Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
[TBL] [Abstract][Full Text] [Related]
17. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.
Ilson BE; Martin DE; Boike SC; Jorkasky DK
J Clin Pharmacol; 1998 May; 38(5):437-41. PubMed ID: 9602957
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
19. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
20. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
